1,287 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by AXQ Capital LP

AXQ Capital LP bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,287 shares of the biotechnology company’s stock, valued at approximately $454,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Wealthfront Advisers LLC lifted its position in shares of United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after buying an additional 18,313,424 shares during the last quarter. Geode Capital Management LLC lifted its holdings in United Therapeutics by 4.3% during the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after purchasing an additional 45,566 shares during the last quarter. FMR LLC boosted its position in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares during the period. Pacer Advisors Inc. increased its stake in shares of United Therapeutics by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after purchasing an additional 30,931 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of United Therapeutics by 12.3% in the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after purchasing an additional 50,409 shares during the period. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, December 30th. The stock was sold at an average price of $356.68, for a total value of $3,566,800.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $919,164.36. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 90,255 shares of company stock worth $32,614,521. 11.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

UTHR has been the topic of a number of analyst reports. UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Stock Down 0.2 %

Shares of NASDAQ UTHR opened at $312.99 on Friday. The company has a market cap of $14.06 billion, a price-to-earnings ratio of 13.75, a PEG ratio of 0.97 and a beta of 0.64. The firm’s fifty day moving average is $345.10 and its 200 day moving average is $357.02. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the business posted $4.36 earnings per share. Equities research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.